Logo image of HLVX

HILLEVAX INC (HLVX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:HLVX - US43157M1027 - Common Stock

2.09 USD
-0.01 (-0.48%)
Last: 9/16/2025, 8:00:01 PM
2.1 USD
+0.01 (+0.48%)
After Hours: 9/16/2025, 8:00:01 PM
Fundamental Rating

3

Overall HLVX gets a fundamental rating of 3 out of 10. We evaluated HLVX against 528 industry peers in the Biotechnology industry. While HLVX has a great health rating, there are worries on its profitability. HLVX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year HLVX has reported negative net income.
  • In the past year HLVX has reported a negative cash flow from operations.
  • HLVX had negative earnings in each of the past 5 years.
  • In the past 5 years HLVX always reported negative operating cash flow.
HLVX Yearly Net Income VS EBIT VS OCF VS FCFHLVX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • HLVX has a Return On Assets of -40.65%. This is comparable to the rest of the industry: HLVX outperforms 58.70% of its industry peers.
  • HLVX has a better Return On Equity (-48.10%) than 66.48% of its industry peers.
Industry RankSector Rank
ROA -40.65%
ROE -48.1%
ROIC N/A
ROA(3y)-54.23%
ROA(5y)-132.64%
ROE(3y)-67.22%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HLVX Yearly ROA, ROE, ROICHLVX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for HLVX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HLVX Yearly Profit, Operating, Gross MarginsHLVX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, HLVX has more shares outstanding
  • The number of shares outstanding for HLVX has been increased compared to 5 years ago.
  • HLVX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
HLVX Yearly Shares OutstandingHLVX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
HLVX Yearly Total Debt VS Total AssetsHLVX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -1.98, we must say that HLVX is in the distress zone and has some risk of bankruptcy.
  • HLVX has a Altman-Z score (-1.98) which is in line with its industry peers.
  • HLVX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.98
ROIC/WACCN/A
WACCN/A
HLVX Yearly LT Debt VS Equity VS FCFHLVX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • HLVX has a Current Ratio of 26.39. This indicates that HLVX is financially healthy and has no problem in meeting its short term obligations.
  • HLVX has a better Current ratio (26.39) than 97.41% of its industry peers.
  • A Quick Ratio of 26.39 indicates that HLVX has no problem at all paying its short term obligations.
  • HLVX's Quick ratio of 26.39 is amongst the best of the industry. HLVX outperforms 97.41% of its industry peers.
Industry RankSector Rank
Current Ratio 26.39
Quick Ratio 26.39
HLVX Yearly Current Assets VS Current LiabilitesHLVX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 57.82% over the past year.
EPS 1Y (TTM)57.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 10.16% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y83.34%
EPS Next 2Y35.78%
EPS Next 3Y22.84%
EPS Next 5Y10.16%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HLVX Yearly Revenue VS EstimatesHLVX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 20M 40M 60M
HLVX Yearly EPS VS EstimatesHLVX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • HLVX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HLVX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HLVX Price Earnings VS Forward Price EarningsHLVX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HLVX Per share dataHLVX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as HLVX's earnings are expected to grow with 22.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.78%
EPS Next 3Y22.84%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for HLVX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HILLEVAX INC

NASDAQ:HLVX (9/16/2025, 8:00:01 PM)

After market: 2.1 +0.01 (+0.48%)

2.09

-0.01 (-0.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06
Earnings (Next)N/A
Inst Owners47.55%
Inst Owner Change0%
Ins Owners1.98%
Ins Owner Change-23.95%
Market Cap104.79M
Revenue(TTM)N/A
Net Income(TTM)-71.10M
Analysts43.33
Price Target2.04 (-2.39%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)45.37%
Min EPS beat(2)22.97%
Max EPS beat(2)67.77%
EPS beat(4)2
Avg EPS beat(4)-8.83%
Min EPS beat(4)-104.08%
Max EPS beat(4)67.77%
EPS beat(8)4
Avg EPS beat(8)-4.94%
EPS beat(12)8
Avg EPS beat(12)10.04%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)11.11%
EPS NY rev (1m)0%
EPS NY rev (3m)15.52%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.71
P/tB 0.71
EV/EBITDA N/A
EPS(TTM)-1.43
EYN/A
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.18
OCFYN/A
SpS0
BVpS2.95
TBVpS2.95
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -40.65%
ROE -48.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.23%
ROA(5y)-132.64%
ROE(3y)-67.22%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.08%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 26.39
Quick Ratio 26.39
Altman-Z -1.98
F-Score7
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.75%
EPS Next Y83.34%
EPS Next 2Y35.78%
EPS Next 3Y22.84%
EPS Next 5Y10.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y63.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year14.22%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y32.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.42%
OCF growth 3YN/A
OCF growth 5YN/A

HILLEVAX INC / HLVX FAQ

Can you provide the ChartMill fundamental rating for HILLEVAX INC?

ChartMill assigns a fundamental rating of 3 / 10 to HLVX.


Can you provide the valuation status for HILLEVAX INC?

ChartMill assigns a valuation rating of 1 / 10 to HILLEVAX INC (HLVX). This can be considered as Overvalued.


What is the profitability of HLVX stock?

HILLEVAX INC (HLVX) has a profitability rating of 1 / 10.


What is the financial health of HILLEVAX INC (HLVX) stock?

The financial health rating of HILLEVAX INC (HLVX) is 7 / 10.